Brand Protection in the Medical Sector: Delhi High Court Curbs 'Novarise' in Landmark Injunction

In a significant development for intellectual property, the Delhi High Court has stepped in to protect the global brand identity of pharmaceutical titan Novartis AG. On December 22, 2025, the Court granted an ad-interim injunction against the partnership firm Novarise Gastro Bariatrics, effectively prohibiting them from using the mark 'NOVARISE' in the medical services sector.

The Conflict: A Case of Phonetic Identity

The dispute centers on the protection of the well-known mark 'NOVARTIS', which has been in use since 1996. The Plaintiff alleged that the Defendants, a partnership firm offering medical consultancy services for diabetes, weight management, and digestive health, adopted the name 'NOVARISE' to illicitly trade upon their global reputation.

Despite receiving cease-and-desist notices in August 2025, the Defendants refused to abandon the mark, arguing that their adoption was "honest" and that adding terms like "Gastro Bariatrics" created sufficient distinction. The Plaintiff, however, asserted that 'NOVARISE' was a mere colorable variation of their brand, with 'NOVAR' serving as the dominant, distinctive, and identical prefix.

Court’s Reasoning: Anatomy of a Trademark

Presiding over the matter, Hon'ble Ms. Justice Manmeet Pritam Singh Arora found that the Defendants’ use of the name posed a clear risk of consumer confusion. The Court emphasized that in the highly sensitive arena of medical and healthcare services, the potential for an unwary patient or consumer to associate a provider like 'Novarise' with a global pharmaceutical giant like 'Novartis' is significant.

The Court dismissed the argument regarding the descriptive suffixes, noting that the inclusion of "Gastro" and "Bariatrics" merely identifies the service, while 'NOVARISE' remains the primary identifier that infringes upon the 'NOVARTIS' mark.

Key Observations from the Bench

The Court’s order highlights the necessity of safeguarding established goodwill:

• "This Court finds merit in the submission of the Plaintiff that the terms Gastro and Bariatrics are generic descriptor of the services rendered by the Defendants and do not add distinctiveness to the said mark."
• "The Defendants who are doctors are bound to have been aware about the enormous reputation of the Plaintiff and there is no plausible reason given in the reply to the cease-and-desist notice for adopting the impugned mark."
• "In the overall conspectus, Plaintiff has made out a prima facie case for the grant of injunction against the Defendants. This court is satisfied that if ad interim injunction is not granted at this stage, irreparable harm/injury would be caused to the Plaintiff."

Implications for Future IP Litigation

With this ruling, the Delhi High Court has reaffirmed its stringent stance on protecting well-known marks from deceptive, near-identical nomenclature in the healthcare space. The order not only restrains the Defendants from using the impugned mark across social media, apps, and physical services but also signals a broader commitment to preventing professional entities from leveraging established corporate goodwill.

The Court has ordered the matter to be listed next in February 2026, where the proceedings for the full trial will continue, placing the onus on the Defendants to justify their branding decisions in the face of what the Court currently views as prima facie infringement.